Jennifer Zachary - Merck President
| MRK Stock | EUR 136.80 1.60 1.16% |
President
Ms. Jennifer Zachary is Executive Vice President, General Counsel of the Company, effective April 16, 2018. Zachary is currently a partner at Covington Burling in the firm food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA requirements for the development, manufacture, and distribution of prescription and overthecounter drugs, biologics, and medical devices. Zachary began her career in FDA Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney Office for the District of Columbia. since 2020.
| Age | 41 |
| Tenure | 4 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | PRESIDENT Age | ||
| Todd Young | Elanco Animal Health | 51 | |
| Sarena Lin | Elanco Animal Health | 48 | |
| James Meer | Elanco Animal Health | 53 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Matthias Heinzel, CEO Board | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Gerhard Schmitz, Head Accounting | ||
| Christine Seidman, Independent Director | ||
| Kathy Warden, Independent Director | ||
| Constantin Fest, Head Relations | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Peter Guenter, CEO Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Marcus Kuhnert, CFO Board | ||
| Peter Wendell, Independent Director | ||
| Friederike Rotsch, Group Compliance | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director | ||
| Dirk Toepfer, Chief Officer | ||
| Pamela Craig, Independent Director | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Kai Beckmann, CEO Board | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.36 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 60.26 % | |||
| Price To Earning | 36.46 X | |||
| Price To Book | 2.77 X | |||
| Price To Sales | 3.80 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.